4D Molecular Therapeutics, Inc. Common Stock

FDMT trades with a staggering 26.72% short interest—among the highest relative to float for its market cap tier—yet sits only 56.9 on RSI, suggesting the stock hasn't experienced the violent squeeze that such shorts might typically trigger. The $0.5B market cap biotech lacks earnings (hence no P/E), pointing to an unprofitable or pre-revenue stage company where fundamentals remain speculative. With neither recent 52-week highs nor extreme overbought conditions, the setup appears structurally vulnerable to either a covering rally if sentiment shifts or continued deterioration if clinical/commercial progress stalls. The elevated short position creates asymmetric risk potential, though the absence of technical confirmation suggests institutional conviction around the bearish thesis remains firm.